Full-Time

Director Global Regulatory Lead

GI & Inflammation

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$177k - $278.1k/yr

+ Short-term incentives + Long-term incentives + 401(k) company match + Tuition reimbursement

Boston, MA, USA

Hybrid

Hybrid work is required under Takeda’s hybrid and remote work policy.

Bachelor's, PharmD, PhD, MD

Category
Legal & Compliance (1)

Get referred to Takeda

See people who can refer or advise you

Requirements
  • A Bachelor's Degree is required; a scientific discipline is strongly preferred.
  • Eight or more years of pharmaceutical industry experience, including six years of regulatory experience or a combination of four or more years of regulatory and/or related experience.
  • Solid working knowledge of the drug development process and regulatory requirements, including knowledge of the United States Food and Drug Administration, European Union, Canada, the rest of the world, and post-marketing requirements.
  • Ability to understand and interpret complex scientific issues and scientific data across multiple projects as they relate to regulatory requirements and strategy.
  • Strong oral and written communication, timeline management, negotiation, integrity, and adaptability skills.
  • Ability to work effectively with others and within global teams and bring working teams together for common objectives.
  • Independent skills in regulatory strategy, including identifying regulatory issues and developing creative solutions and risk-mitigation strategies.
Responsibilities
  • Define, develop, and lead global strategies to maximize global regulatory success for complex and/or multiple projects.
  • Provide strategic and tactical advice to teams to achieve timely and efficient development and maintenance of programs while ensuring compliance with applicable regulatory requirements.
  • Provide leadership and development for direct reports, including global regulatory leads responsible for designing and executing global regulatory strategies with regional counterparts.
  • Lead Global Regulatory Teams and applicable sub-working groups, represent them at project team meetings, and provide tactical guidance to ensure global regulatory strategies are updated and executed.
  • Ensure global regulatory strategies are effectively implemented and maintained in line with changing regulatory and business needs, and lead adaptations to regulatory strategy.
  • Keep project team colleagues, line management, and key stakeholders informed of developments that may affect regulatory success.
  • Anticipate risks, develop solutions to identified risks, and discuss them with teams and management.
  • Oversee or be accountable for all United States Food and Drug Administration submissions and approvals for assigned projects, including leading all submission types.
  • Serve as a direct point of contact with health authorities and lead and manage Food and Drug Administration meetings.
  • Work with regional regulatory leads, other functions, and vendors to ensure global regulatory submissions are provided to local affiliates in compliance with local regulations and maintain product compliance.
  • Oversee vendors' regulatory activities and submissions for projects within scope.
  • Participate with influence in or lead departmental and cross-functional task forces and initiatives.
  • Serve as lead regulatory reviewer in due diligence for licensing opportunities.
  • Partner with global market access colleagues to lead interactions with joint regulatory, health agency, and health technology assessment bodies on product-specific value evidence topics.
  • Monitor and anticipate trends affecting regulatory and access environments to strengthen product development plans and adapt regulatory strategies in a timely manner.
  • Demonstrate Takeda leadership behaviors.
Desired Qualifications
  • An advanced degree in a scientific discipline, such as a Doctor of Pharmacy, Doctor of Philosophy, or Doctor of Medicine, is strongly preferred.
  • Experience reviewing, authoring, or managing components of regulatory submissions.
  • Knowledge of regulatory requirements in the United States Food and Drug Administration, European Union, Canada, the rest of the world, and post-marketing environments.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Orzeyful launch opens a new neurology franchise with disease-modifying pricing power.
  • Takeda’s Q1 fiscal 2026 revenue rose 10.2% reported, driven by new launches.
  • Boltz partnership gives Takeda organization-wide AI access for structure prediction and generative design.

What critics are saying

  • Boston jurors found Takeda liable on May 18, 2026; appeal runs through 2026.
  • Takeda booked roughly 403.5 billion yen for Amitiza exposure, crushing fiscal 2025 profit.
  • Takeda will cut about 4,500 jobs in fiscal 2026, signaling integration strain after Shire.

What makes Takeda unique

  • Takeda’s Orzeyful became the first FDA-approved orexin therapy on August 5, 2026.
  • Takeda already won China approval for Orzeyful in July 2026, extending first-mover advantage.
  • Takeda’s dengue vaccine is India’s first approved Japanese dengue vaccine, strengthening emerging-market positioning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.

Yahoo Finance
Jul 30th, 2026
Takeda Pharmaceutical Q1 results on track as new launches offset mature product declines

Takeda Pharmaceutical reported first-quarter fiscal 2026 results aligned with its full-year outlook. Revenue totalled JPY 1.22 trillion, up 10.2% on an actual foreign-exchange basis but down 0.5% at constant exchange rates. Core operating profit reached JPY 358.9 billion, rising 11.5% on an actual FX basis. The company's core inline brands, representing 58% of total revenue, grew 2.3% at constant exchange rates. New launches accounted for 4% of revenue but grew 22.6%, supported by FRUZAQLA, LIVTENCITY, ADZYNMA and QDENGA. Takeda is preparing three product launches: ORZEYFUL for narcolepsy type 1, rusfertide for polycythemia vera, and zasocitinib for psoriasis. The company maintained its fiscal 2026 guidance and expects to generate JPY 650 billion to JPY 750 billion in free cash flow.

Nikkei Asia
Jul 21st, 2026
India approves first dengue vaccine from Japan's Takeda

India has approved Takeda Pharmaceutical's dengue vaccine, marking the country's first approved vaccine for the disease. The Japanese drugmaker received regulatory approval as authorities seek to combat dengue's accelerating transmission across India. Dengue, a mosquito-borne viral infection, poses a significant public health challenge in tropical regions. The approval represents a milestone in India's efforts to address the disease burden. The vaccine's introduction comes as dengue cases continue to rise in the country, making prevention efforts increasingly urgent for Indian health authorities.

Business Wire
Jun 24th, 2026
Julie Kim becomes Takeda's president and CEO as pharmaceutical giant prepares three major launches

Takeda has appointed Julie Kim as Representative Director, President and CEO, completing an 18-month transition. Shareholders elected Kim as an internal director during the company's 150th Annual General Meeting in Osaka, after which the Board appointed her to the top role. Former president and CEO Christophe Weber retired following the meeting. Kim joined Takeda in 2019 through the Shire acquisition and previously held roles including president of the Plasma-Derived Therapies Business Unit and president of the U.S. Business Unit. She brings over three decades of global healthcare experience. Shareholders also elected three new external directors: Bruce Broussard, Koichiro Kimura and Dr Paul Stoffels. Takeda's Board now comprises 11 members, with eight serving as external directors. The company plans three major launches over the next 12 months.